Our News

Press Releases
Presentations

Jun 1, 2024 | American Society of Clinical Oncology (ASCO)A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

Apr 5, 2024 | American Association for Cancer Research (AACR)Anchored IL-12 synergizes with an epigenetic modulator to promote immune remodeling and overcome anti-PD1-refractory murine tumors

Nov 3, 2023 | Society for Immunotherapy of Cancer (SITC):Improved immunologic and therapeutic activity of anchored interleukin (IL)-12 immunotherapy in combination with cytotoxic chemotherapy and immune checkpoint inhibitor in a head and neck cancer model

Oct 14, 2023 | Veterinary Cancer Society:Tolerability and Activity of Anchored Canine Interleukin-12 (cANK-101) in Pet Dogs with Advanced Malignant Melanoma

Oct 12, 2023 | European Organization for Research and Treatment of Cancer (EORTC):Preclinical pharmacokinetic (PK) and tumour growth inhibition (TGI) modelling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoural administration for solid cancer

Apr 19, 2023 | American Association for Cancer Research (AACR)Preliminary Results of an Exploratory Phase I Clinical Trial of Anchored Canine Interleukin-12 (cANK-101) in Dogs with Advanced Oral Malignant Melanoma

Nov 10, 2022 | Society for Immunotherapy of Cancer (SITC) Presentation:Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response

Apr 10, 2022 | American Association for Cancer Research (AACR) Presentation:Intratumoral delivery of aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response

Oct 14, 2021 | Society for Immunotherapy of Cancer (SITC) Presentation:Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity

Publications

Oct 7, 2024 | Journal for ImmunoTherapy of CancerAlum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models

Dec 8, 2023 | JCI Insight:Intratumoral aluminum hydroxide–anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment

Jan 10, 2022 | Nature Biomedical Engineering:Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity

Jun 2, 2022 | Expert Opinion on Drug Delivery Manuscript:Intratumorally anchored cytokine therapy